Literature DB >> 29269105

Disturbed phospholipid metabolism in serine biosynthesis defects revealed by metabolomic profiling.

Kevin E Glinton1, Paul J Benke2, Matthew A Lines3, Michael T Geraghty3, Pranesh Chakraborty3, Osama Y Al-Dirbashi4, Yi Jiang5, Adam D Kennedy6, Michael S Grotewiel7, V Reid Sutton8, Sarah H Elsea8, Ayman W El-Hattab9.   

Abstract

Serine biosynthesis defects are autosomal recessive metabolic disorders resulting from the deficiency of any of the three enzymes involved in de novo serine biosynthesis, specifically phosphoglycerate dehydrogenase (PGDH), phosphoserine aminotransferase (PSAT), and phosphoserine phosphatase (PSP). In this study, we performed metabolomic profiling on 4 children with serine biosynthesis defects; 3 with PGDH deficiency and 1 with PSAT deficiency. The evaluations were performed at baseline and with serine and glycine supplementation. Metabolomic profiling performed at baseline showed low phospholipid species, including glycerophosphocholine, glycerophosphoethanolamine, and sphingomyelin. All children had low serine and glycine as expected. Low glycerophosphocholine compounds were found in 4 children, low glycerophosphoethanolamine compounds in 3 children, and low sphingomyelin species in 2 children. Metabolic profiling with serine and glycine supplementation showed normalization of most of the low phospholipid compounds in the 4 children. Phospholipids are the major component of plasma and intracellular membranes, and phosphatidylcholine is the most abundant phospholipid of all mammalian cell types and subcellular organelles. Phosphatidylcholine is of particular importance for the nervous system, where it is essential for neuronal differentiation. The observed low phosphatidylcholine species in children with serine biosynthesis defects that improved after serine supplementation, supports the role of serine as a significant precursor for phosphatidylcholine. The vital role that phosphatidylcholine has during neuronal differentiation and the pronounced neurological manifestations in serine biosynthesis defects suggest that phosphatidylcholine deficiency occurring secondary to serine deficiency may have a significant contribution to the development of the neurological manifestations in individuals with serine biosynthesis defects.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29269105     DOI: 10.1016/j.ymgme.2017.12.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  A yeast-based complementation assay elucidates the functional impact of 200 missense variants in human PSAT1.

Authors:  Amy Sirr; Russell S Lo; Gareth A Cromie; Adrian C Scott; Julee Ashmead; Mirutse Heyesus; Aimée M Dudley
Journal:  J Inherit Metab Dis       Date:  2020-02-27       Impact factor: 4.982

2.  Assessment of the effects of repeated freeze thawing and extended bench top processing of plasma samples using untargeted metabolomics.

Authors:  Kelli Goodman; Matthew Mitchell; Anne M Evans; Luke A D Miller; Lisa Ford; Bryan Wittmann; Adam D Kennedy; Douglas Toal
Journal:  Metabolomics       Date:  2021-03-11       Impact factor: 4.290

3.  Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA).

Authors:  Teresa D Douglas; L Kristin Newby; Julie Eckstrand; Douglas Wixted; Rani H Singh
Journal:  Mol Genet Metab Rep       Date:  2020-10-14

4.  Adult diagnosis of congenital serine biosynthesis defect: A treatable cause of progressive neuropathy.

Authors:  Sarah Debs; Carlos R Ferreira; Catherine Groden; H Jeffrey Kim; Kelly A King; Monique C King; Tanya Lehky; Edward W Cowen; Laura H Brown; Melissa Merideth; Carter M Owen; Ellen Macnamara; Camilo Toro; William A Gahl; Ariane Soldatos
Journal:  Am J Med Genet A       Date:  2021-06-04       Impact factor: 2.578

Review 5.  The Microenvironment Is a Critical Regulator of Muscle Stem Cell Activation and Proliferation.

Authors:  John H Nguyen; Jin D Chung; Gordon S Lynch; James G Ryall
Journal:  Front Cell Dev Biol       Date:  2019-10-29

6.  Mutations in PCYT2 disrupt etherlipid biosynthesis and cause a complex hereditary spastic paraplegia.

Authors:  Frédéric M Vaz; John H McDermott; Mariëlle Alders; Saskia B Wortmann; Stefan Kölker; Mia L Pras-Raves; Martin A T Vervaart; Henk van Lenthe; Angela C M Luyf; Hyung L Elfrink; Kay Metcalfe; Sara Cuvertino; Peter E Clayton; Rebecca Yarwood; Martin P Lowe; Simon Lovell; Richard C Rogers; Antoine H C van Kampen; Jos P N Ruiter; Ronald J A Wanders; Sacha Ferdinandusse; Michel van Weeghel; Marc Engelen; Siddharth Banka
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

7.  Juvenile-onset PSAT1-related neuropathy: A milder phenotype of serine deficiency disorder.

Authors:  Yu Shen; Yun Peng; Pengcheng Huang; Yilei Zheng; Shumeng Li; Kaiyan Jiang; Meihong Zhou; Jianwen Deng; Min Zhu; Daojun Hong
Journal:  Front Genet       Date:  2022-08-16       Impact factor: 4.772

8.  Characterization of ETFDH and PHGDH Mutations in a Patient with Mild Glutaric Aciduria Type II and Serine Deficiency.

Authors:  Amanat Ali; Nahid Al Dhahouri; Fatmah Saeed Ali Almesmari; Waseem Mahmoud Fathalla; Fatma Al Jasmi
Journal:  Genes (Basel)       Date:  2021-05-08       Impact factor: 4.096

9.  Zika virus infection modulates the metabolomic profile of microglial cells.

Authors:  Fodé Diop; Thomas Vial; Pauline Ferraris; Sineewanlaya Wichit; Michèle Bengue; Rodolphe Hamel; Loïc Talignani; Florian Liegeois; Julien Pompon; Hans Yssel; Guillaume Marti; Dorothée Missé
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

10.  Comparison of Untargeted Metabolomic Profiling vs Traditional Metabolic Screening to Identify Inborn Errors of Metabolism.

Authors:  Ning Liu; Jing Xiao; Charul Gijavanekar; Kirk L Pappan; Kevin E Glinton; Brian J Shayota; Adam D Kennedy; Qin Sun; V Reid Sutton; Sarah H Elsea
Journal:  JAMA Netw Open       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.